Recombinant Human MIG (CXCL9)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | MIG, a CXC chemokine, is produced by IFN stimulated monocytes, macrophages and endothelial cells. It signals through the CXCR3 receptor. MIG selectively chemoattracts Th1 lymphocytes, and also exerts other activities including inhibition of tumor growth, angiogenesis, and inhibition of colony formation of hematopoietic progenitors. Human MIG is active on murine cells. Recombinant human MIG is an 11.7 kDa protein containing 103 amino acid residues, including the four highly conserved cysteine residues present in CXC chemokines. |
---|---|
BiologicalActivity | Determined by its ability to chemoattract human peripheral blood T lymphocytes using a concentration range of 10.0-100.0 ng/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human MIG (CXCL9) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.